Azimuth Capital Management LLC raised its position in shares of Allergan PLC. (NYSE:AGN) by 1.7% during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 13,291 shares of the company’s stock after buying an additional 225 shares during the period. Azimuth Capital Management LLC’s holdings in Allergan PLC. were worth $3,175,000 at the end of the most recent quarter.
Several other institutional investors have also modified their holdings of the stock. Crestwood Advisors Group LLC purchased a new stake in shares of Allergan PLC. during the first quarter valued at approximately $103,000. Feltz Wealth PLAN Inc. purchased a new stake in shares of Allergan PLC. during the first quarter valued at approximately $107,000. Enterprise Financial Services Corp boosted its stake in shares of Allergan PLC. by 62.7% in the first quarter. Enterprise Financial Services Corp now owns 462 shares of the company’s stock valued at $110,000 after buying an additional 178 shares during the last quarter. JNBA Financial Advisors boosted its stake in shares of Allergan PLC. by 2.5% in the first quarter. JNBA Financial Advisors now owns 487 shares of the company’s stock valued at $116,000 after buying an additional 12 shares during the last quarter. Finally, Webster Bank N. A. boosted its stake in shares of Allergan PLC. by 31.0% in the first quarter. Webster Bank N. A. now owns 520 shares of the company’s stock valued at $124,000 after buying an additional 123 shares during the last quarter. Institutional investors own 84.77% of the company’s stock.
Allergan PLC. (NYSE AGN) opened at 232.88 on Friday. Allergan PLC. has a 52 week low of $184.50 and a 52 week high of $256.80. The firm has a market capitalization of $78.06 billion, a price-to-earnings ratio of 7.10 and a beta of 1.16. The company has a 50 day moving average price of $245.93 and a 200-day moving average price of $238.13.
Allergan PLC. (NYSE:AGN) last issued its earnings results on Thursday, August 3rd. The company reported $4.02 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $3.95 by $0.07. Allergan PLC. had a return on equity of 7.37% and a net margin of 79.17%. The company had revenue of $4.01 billion during the quarter, compared to the consensus estimate of $3.95 billion. During the same period in the previous year, the company posted $3.35 EPS. The firm’s revenue for the quarter was up 8.8% compared to the same quarter last year. Equities analysts predict that Allergan PLC. will post $16.27 earnings per share for the current year.
The company also recently declared a quarterly dividend, which will be paid on Friday, September 15th. Investors of record on Friday, August 18th will be paid a $0.70 dividend. The ex-dividend date is Wednesday, August 16th. This represents a $2.80 annualized dividend and a yield of 1.20%. Allergan PLC.’s dividend payout ratio (DPR) is presently 9.95%.
COPYRIGHT VIOLATION NOTICE: “Azimuth Capital Management LLC Purchases 225 Shares of Allergan PLC. (AGN)” was first posted by Community Financial News and is owned by of Community Financial News. If you are reading this story on another domain, it was illegally stolen and reposted in violation of United States & international copyright & trademark legislation. The original version of this story can be read at https://www.com-unik.info/2017/08/12/azimuth-capital-management-llc-acquires-225-shares-of-allergan-plc-agn-updated-updated.html.
Several brokerages recently commented on AGN. UBS AG reissued an “outperform” rating and issued a $275.00 price target on shares of Allergan PLC. in a research note on Wednesday. Deutsche Bank AG reissued a “buy” rating and issued a $278.00 price target (up previously from $273.00) on shares of Allergan PLC. in a research note on Wednesday. BidaskClub cut Allergan PLC. from a “buy” rating to a “hold” rating in a research note on Wednesday. Wells Fargo & Company reissued an “outperform” rating and issued a $280.00 price target (up previously from $270.00) on shares of Allergan PLC. in a research note on Wednesday. Finally, Credit Suisse Group set a $288.00 price target on Allergan PLC. and gave the company a “buy” rating in a research note on Saturday, August 5th. Eight equities research analysts have rated the stock with a hold rating and fifteen have assigned a buy rating to the company’s stock. The company has an average rating of “Buy” and a consensus target price of $274.49.
In related news, Director Nesli Basgoz sold 1,889 shares of the business’s stock in a transaction on Thursday, May 18th. The stock was sold at an average price of $220.45, for a total value of $416,430.05. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Insiders own 0.36% of the company’s stock.
About Allergan PLC.
Allergan, Inc is a multi-specialty healthcare company. The Company focuses on developing and commercializing pharmaceuticals, biologics, medical devices and over-the-counter (OTC) products. It discovers, develops and commercializes a range of products for the ophthalmic, neurological, medical aesthetics, medical dermatology, breast aesthetics, urological and other specialty markets.
What are top analysts saying about Allergan PLC.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Allergan PLC. and related companies.